Overview
- The Alliance A071401 trial enrolled patients with recurrent or progressive grade 2–3 meningiomas carrying NF2 mutations or CDK pathway alterations.
- Among the first 24 patients treated, 58% had no tumor progression at six months after starting abemaciclib.
- Median progression-free survival was 10 months, and median overall survival was 29 months.
- Safety findings were consistent with CDK inhibitors, with common diarrhea and fatigue, and about one quarter of patients having grade 3–4 events.
- The NCI-sponsored, multi-institutional study was published in Nature Medicine, and investigators emphasized the need for confirmatory research.